tbuckley/cabot-search huggingface dataset:
Hospitalisation patterns among children exposed to childhood adversity: a population-based cohort study of half a million children
Authors: Naja Hulvej Rod, Jessica Bengtsson, Leonie K Elsenburg, David Taylor-Robinson, Andreas Rieckmann
Journal: The Lancet Public Health (2021)

Children who are exposed to adversities might be more susceptible to disease development during childhood and in later life due to impaired physiological and mental development. To explore this hypothesis, we assessed hospitalisation patterns through childhood and into adult life among those exposed to different trajectories of adversities during childhood.For this population-based cohort study, we used annually updated data from Danish nationwide registers covering more than half a million children (aged 0-15 years) born between 1994 and 2001. Children who were alive and resident in Denmark on their 16th birthday were included in the analysis. Cluster analysis was used to divide children into five distinct trajectories according to their experience of childhood adversities, including poverty and material deprivation, loss or threat of loss within the family, and aspects of family dynamics. To describe comprehensively the disease patterns experienced by these groups of children, we assessed the associations of each adversity trajectory with hospital admission patterns according to the entire spectrum of disease diagnoses in the International Classification of Diseases 10th edition, from birth to 24 years of age, using survival models.508 168 children born between Jan 1, 1994, and Dec 31, 2001, were followed up until Dec 31, 2018, capturing more than 3·8 million hospital admissions from birth to early adulthood. Hospitalisation rates were consistently higher in all four adversity groups compared with the low adversity group. The high adversity group (14 577 children, 3%), who were exposed to adversities of deprivation, family loss, and negative family dynamics, had a markedly higher rate of hospitalisations across all ages. For example, we observed 243 additional hospital admissions per 1000 person-years (95% CI 238-248) in the high versus low adversity group for those aged 16-24 years. These associations were particularly strong for diagnoses related to injuries, unspecified symptoms, and factors influencing health service contacts (eg, health screening and observation). They also covered a considerable burden of respiratory and infectious diseases, congenital malformations, diseases of the nervous system (especially in early life), mental and behavioural diagnoses, and diagnoses related to pregnancy and childbirth in early adult life.The close linkage between childhood adversities and poor lifelong health outcomes highlights a need for public health and policy attention on improving the socioeconomic circumstances children are born into to prevent the early emergence of health inequalities.None.
385O Automated detection of microsatellite status in early colon cancer (CC) using artificial intelligence (AI) integrated infrared (IR) imaging on unstained samples from the AIO ColoPredictPlus 2.0 (CPP) registry study
Authors: F. Großerüschkamp, S.M. Schörner, A-L. Kraeft, D. Schuhmacher, C. Sternemann, H. Jütte, I. Feder, S. Wisser, C. Lugnier, O. Overheu, D. Arnold, C. Teschendorf, L. Mueller, W. Uhl, N. Timmesfeld, A. Mosig, A. Reinacher-Schick, K. Gerwert, A. Tannapfel
Journal: Annals of Oncology (2021)
659MO Avelumab (A) as the basis of neoadjuvant chemotherapy (NAC) regimen in platinum eligible and ineligible patients (pts) with non-metastatic muscle invasive bladder cancer (NM-MIBC)
Authors: N. Martinez Chanza, A. Carnot, P. Barthelemy, V. Casert, B. Sautois, J. Van den Brande, V. Vanhaudenarde, L. Staudacher, E. Seront, S. Culine, M. Gizzi, T. Gil, M. Paesmans, N. Kotecki, M. Ignatiadis, S. Albisinni, J.C. Fantoni, T. Tricard, T. Roumeguere, A.H. Awada
Journal: Annals of Oncology (2021)
Toward Equitable COVID-19 Vaccine Distribution—Building Trust and Investing in Social Services
Authors: Lilia Cervantes
Journal: JAMA Network Open (2021)

Savanna L. Carson, PhD; Alejandra Casillas, MD, MSHS; Yelba Castellon-Lopez, MD, MS; Lisa N. Mansfield, PhD, MSN, RN; D'Ann Morris, MPA; Juan Barron, BA; Ejiro Ntekume, MPH; Raphael Landovitz, MD, MSc; Stefanie D. Vassar, MS; Keith C. Norris, MD, PhD; Steven M. Dubinett, MD; Nanibaa' A. Garrison, PhD; Arleen F. Brown, MD, PhD
Development of lung diffusion to adulthood following extremely preterm birth
Authors: Emma Satrell, Hege Clemm, Ola Drange Røksund, Karl Ove Hufthammer, Einar Thorsen, Thomas Halvorsen, Maria Vollsæter
Journal: European Respiratory Journal (2021)

Gas exchange in extremely preterm (EP) infants must take place in fetal lungs. Childhood lung diffusing capacity of the lung for carbon monoxide (DLCO) is reduced; however, longitudinal development has not been investigated. We describe the growth of DLCO and its subcomponents to adulthood in EP compared with term-born subjects.Two area-based cohorts born at gestational age ≤28 weeks or birthweight ≤1000 g in 1982-1985 (n=48) and 1991-1992 (n=35) were examined twice, at ages 18 and 25 years and 10 and 18 years, respectively, and compared with matched term-born controls. Single-breath DLCO was measured at two oxygen pressures, with subcomponents (membrane diffusion (DM) and pulmonary capillary blood volume (VC)) calculated using the Roughton-Forster equation.Age-, sex- and height-standardised transfer coefficients for carbon monoxide (KCO) and DLCO were reduced in EP compared with term-born subjects, and remained so during puberty and early adulthood (p-values for all time-points and both cohorts ≤0.04), whereas alveolar volume (VA) was similar. Development occurred in parallel to term-born controls, with no signs of pubertal catch-up growth nor decline at age 25 years (p-values for lack of parallelism within cohorts 0.99, 0.65, 0.71, 0.94 and 0.44 for z-DLCO, z-VA, z-KCO, DM and VC, respectively). Split by membrane and blood volume components, findings were less clear; however, membrane diffusion seemed most affected.Pulmonary diffusing capacity was reduced in EP compared with term-born subjects, and development from childhood to adulthood tracked in parallel to term-born subjects, with no signs of catch-up growth nor decline at age 25 years.
The presence of NAFLD influences the transition of metabolically healthy to metabolically unhealthy obesity and the ten-year cardiovascular disease risk: A population-based cohort study
Authors: Matina Kouvari, Christina Chrysohoou, John Skoumas, Christos Pitsavos, Demosthenes B. Panagiotakos, Christos S. Mantzoros
Journal: Metabolism (2021)
603P Objective computerized cognitive assessment in men with metastatic castrate-resistant prostate cancer (mCRPC) randomly receiving darolutamide or enzalutamide in the ODENZA trial
Authors: E. Colomba, S.F. Jonas, J-C. Eymard, R. Delva, P.E. Brachet, Y. Neuzillet, N. Penel, G. Roubaud, E. Bompas, H. Mahammedi, R. Longo, C. Helissey, P. Barthelemy, D. Borchiellini, A. Hasbini, F. Priou, C. Saldana, E. Voog, S. Foulon, K. Fizazi
Journal: Annals of Oncology (2021)
764P Survey on the practical implementation of BRCA gene and HRD-testing and PARP-inhibitor management in Germany: A national NOGGO/JAGO-AGO intergroup study
Authors: J. Baum, B.D. Nguyen, P. Meyer-Wilmes, A. Kreklau, C. Buschmann, S. Boz, C. Fotopoulou, R. Chekerov, E.I. Braicu, M. Hummel, J. Sehouli, K. Pietzner
Journal: Annals of Oncology (2021)
613P Chromosomal instability (CIN) biomarker in circulating tumor cells (CTC) may predict for therapy resistance in metastatic castration-resistant prostate cancer (mCRPC)
Authors: N.M. Keegan, J. Schonhoft, E. Barnett, E.D. Cohn, J.L. Zhao, E.A. Carbone, M.R. Zanone, A. Anderson, R. Wenstrup, H.I. Scher
Journal: Annals of Oncology (2021)
LBA16 KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC
Authors: J. Cortés, D.W. Cescon, H.S. Rugo, S-A. Im, M. Md Yusof, C. Gallardo, O. Lipatov, C.H. Barrios, J. Perez-Garcia, H. Iwata, N. Masuda, M. Torregroza Otero, E. Gokmen, S. Loi, Z. Guo, X. Zhou, V. Karantza, W. Pan, P. Schmid
Journal: Annals of Oncology (2021)
116P Real-world and in silico incidence of fibroblast growth factor receptor (FGFR) 1-4 molecular alterations across multiple cancer types
Authors: L. Angelats, A. Indacochea, I. Victoria Ruiz, D. Moreno, P. Sole Bentz, B. Mellado, E. Pineda, L. Gaba Garcia, M. Muñoz Mateu, M. Vidal, T. Saurí, F.M. Esposito, L. Ferrer, O. Martínez-Sáez, N. Basté, V. Ortega, L. Jolis, L. Mezquita, A. Prat, J. Garcia-Corbacho
Journal: Annals of Oncology (2021)
Temporal Association Between Episodes of Atrial Fibrillation and Risk of Ischemic Stroke
Authors: Daniel E. Singer, Paul D. Ziegler, Jodi L. Koehler, Shantanu Sarkar, Rod S. Passman
Journal: JAMA Cardiology (2021)

<h3>Importance</h3> Understanding the temporal association between atrial fibrillation (AF) and ischemic stroke informs our understanding of the AF-stroke mechanism and treatment of paroxysmal AF. <h3>Objective</h3> To define the temporal association between episodes of AF and stroke in patients with cardiac implantable electronic devices (CIEDs). <h3>Design, Setting, and Participants</h3> In this case-crossover study, data from a large national electronic health record database were linked with a single-vendor database of heart rhythm records of patients with CIEDs capable of continuous heart rhythm monitoring. Patients with CIEDs who sustained an ischemic stroke who also had 120 days of continuous remote rhythm monitoring prestroke were included. Data were collected from January 2007 to March 2017, and data were analyzed from November 2019 to June 2020. <h3>Exposure</h3> AF for 5.5 hours or more on any given day during days 1 to 30 vs days 91 to 120 prestroke. <h3>Main Outcomes and Measures</h3> Odds ratio for stroke comparing AF during days 1 to 30 vs 91 to 120 prestroke. This analysis was planned prior to the study. <h3>Results</h3> From 466 635 patients included in both the Optum electronic health record and CareLink databases, 891 patients with CIEDs and ischemic stroke with continuous monitoring in the 120 days prestroke were identified. Of 891 included patients, 575 (64.5%) were male, and the median (interquartile range) age was 76 (67-82) years. The vast majority of patients with stroke had either no AF meeting the threshold duration of 5.5 hours or more in both the case and control periods (682 of 891 [76.5%]) or AF of 5.5 hours or more in both periods (143 of 891 [16.0%]). For those not meeting the 5.5-hour AF threshold in either period, there was no or very little AF throughout the 120 days prestroke. A total of 66 patients had informative, discordant arrhythmic states, with 52 having AF of 5.5 hours or more in the case period vs 14 in the control period (odds ratio [OR], 3.71; 95% CI, 2.06-6.70). Stroke risk was increased most in days 1 to 5 following an AF episode (OR, 5.00; 95% CI, 2.62-9.55). AF greater than 23 hours on a given day was associated with the clearest increase in stroke risk (OR, 5.00; 95% CI, 2.08-12.01). <h3>Conclusions and Relevance</h3> In this large cohort of patients with CIEDs and continuous rhythm monitoring prior to ischemic stroke, excess stroke risk above baseline was highest within 5 days of an episode of AF of 5.5 hours or more in duration and diminished rapidly thereafter. Our findings are consistent with the traditional view that AF is directly and transiently associated with ischemic stroke. These results provide support for trials of time-delimited anticoagulation for patients with infrequent multihour episodes of AF and rigorous, continuous rhythm monitoring.
1759MO Associations between sarcopenia and gut microbiota in patients (pts) with metastatic renal cell carcinoma (mRCC) and breast cancer (BC)
Authors: Z.B. Zengin, J. Malhotra, S.K. Salgia, N. Dizman, S. Yost, N. Chawla, A. Govindarajan, J. Hsu, N. Salgia, P.G. Bergerot, L. Meza, A. Chehrazi-Raffle, R. Muddasani, J. Gillece, Y. Yuan, S. Highlander, S.K. Pal
Journal: Annals of Oncology (2021)
1106P Phase I study of hepatic intralesional rose bengal disodium (PV10), an autolytic immunotherapy, in metastatic neuroendocrine neoplasms
Authors: T.J. Price, G. Cehic, E. Wachter, R. Sebben, J. Reid, A.M.I. Alawawdeh, M. McGregor, I. Kirkwood, D. Rodrigues, S. Neuhaus, G. Maddern
Journal: Annals of Oncology (2021)
1541P Real-world data from patients with gastrointestinal stromal tumors (GIST) treated in Dutch GIST expertise centers
Authors: N.S. IJzerman, M. Mohammadi, D. Den Hollander, I.M.E. Desar, D.J. Grünhagen, A.K.L. Reyners, R.H. Mathijssen, H. Gelderblom, N. Steeghs
Journal: Annals of Oncology (2021)
Understanding the origins of musicality requires reconstructing the interactive dance between music-specific adaptations, exaptations, and cultural creations
Authors: Laurel J. Trainor
Journal: Behavioral and Brain Sciences (2021)

Abstract The evolutionary origins of complex capacities such as musicality are not simple, and likely involved many interacting steps of musicality-specific adaptations, exaptations, and cultural creation. A full account of the origins of musicality needs to consider the role of ancient adaptations such as credible singing, auditory scene analysis, and prediction-reward circuits in constraining the emergence of musicality.
Thoughts on vigor in the motor and cognitive domains
Authors: Takashi Hanakawa
Journal: Behavioral and Brain Sciences (2021)

Abstract We feel exhausted after working mentally hard even while just sitting on a chair, suggesting the concept of cognitive vigor. Do movement vigor and cognitive vigor share control mechanisms? Functions of the basal ganglia-cortical circuits, which are regulated by the midbrain dopaminergic system, appear to underlie both movement vigor and cognitive vigor.
Epitranscriptomics modifier pentostatin indirectly triggers Toll-like receptor 3 and can enhance immune infiltration in tumors
Authors: Marina Tusup, Thomas M. Kündig, Steve Pascolo
Journal: Molecular Therapy (2021)

The adenosine deaminase inhibitor 2′-deoxycoformycin (pentostatin, Nipent) has been used since 1982 to treat leukemia and lymphoma, but its mode of action is still unknown. Pentostatin was reported to decrease methylation of cellular RNA. We discovered that RNA extracted from pentostatin-treated cells or mice has enhanced immunostimulating capacities. Accordingly, we demonstrated in mice that the anticancer activity of pentostatin required Toll-like receptor 3, the type I interferon receptor, and T cells. Upon systemic administration of pentostatin, type I interferon is produced locally in tumors, resulting in immune cell infiltration. We combined pentostatin with immune checkpoint inhibitors and observed synergistic anti-cancer activities. Our work identifies pentostatin as a new class of an anticancer immunostimulating drug that activates innate immunity within tumor tissues and synergizes with systemic T cell therapies. The adenosine deaminase inhibitor 2′-deoxycoformycin (pentostatin, Nipent) has been used since 1982 to treat leukemia and lymphoma, but its mode of action is still unknown. Pentostatin was reported to decrease methylation of cellular RNA. We discovered that RNA extracted from pentostatin-treated cells or mice has enhanced immunostimulating capacities. Accordingly, we demonstrated in mice that the anticancer activity of pentostatin required Toll-like receptor 3, the type I interferon receptor, and T cells. Upon systemic administration of pentostatin, type I interferon is produced locally in tumors, resulting in immune cell infiltration. We combined pentostatin with immune checkpoint inhibitors and observed synergistic anti-cancer activities. Our work identifies pentostatin as a new class of an anticancer immunostimulating drug that activates innate immunity within tumor tissues and synergizes with systemic T cell therapies.
121MO Acute toxicity associated with a 3-week versus a standard 5-week regimen for locoregional breast radiotherapy delivered in the UNICANCER HypoG-01 phase III trial
Authors: S. Rivera, T. Brion, Y. Kirova, S. Racadot, M. Benchalal, J-B. Clavier, C. Brunaud, M-E. Fouche-Chand, D. Argo-Leignel, K. Peignaux, A. Benyoucef, D. Pasquier, P. Guilbert, J. Blanchecotte, A. Richard Tallet, A. Lamrani-Ghaouti, N. Bonnet, S. Michiels, G. Auzac, E. Karamouza
Journal: Annals of Oncology (2021)
Corrigendum to “Photo-crosslinkable, injectable sericin hydrogel as 3D biomimetic extracellular matrix for minimally invasive repairing cartilage” [biomaterials 163 (2018) 89–104]
Authors: Chao Qi, Jia Liu, Yang Jin, Luming Xu, Guobin Wang, Zheng Wang, Lin Wang
Journal: Biomaterials (2021)
Inducible cardiomyocyte injury within the atrioventricular conduction system uncovers latent regenerative capacity in mice
Authors: Lin Wang, Minoti Bhakta, Antonio Fernandez-Perez, Nikhil V. Munshi
Journal: Journal of Clinical Investigation (2021)

The cardiac conduction system (CCS) ensures regular contractile function, and injury to any of its components can cause cardiac dysrhythmia. Although all cardiomyocytes (CMs) originate from common progenitors, the CCS is composed of biologically distinct cell types with unique functional and developmental characteristics. In contrast to ventricular cardiomyocytes, which continue to proliferate after birth, most CCS cells terminally exit the cell cycle during fetal development. Although the CCS should thus provide a poor substrate for postnatal injury repair, its regenerative capacity remains untested. Here, we describe a genetic system for ablating CMs that reside within the atrioventricular conduction system (AVCS). Adult mouse AVCS ablation resulted in regenerative failure characterized by persistent atrioventricular conduction defects and contractile dysfunction. In contrast, AVCS injury in neonatal mice led to recovery in a subset of these mice, thus providing evidence for CCS plasticity. Furthermore, CM proliferation did not appear to completely account for the observed functional recovery, suggesting that mechanisms regulating recovery from dysrhythmia are likely to be distinct from cardiac regeneration associated with ventricular injury. Taken together, we anticipate that our results will motivate further mechanistic studies of CCS plasticity and enable the exploration of rhythm restoration as an alternative therapeutic strategy.
Author Correction: Epigenetic scarring of exhausted T cells hinders memory differentiation upon eliminating chronic antigenic stimulation
Authors: Mohamed S. Abdel-Hakeem, Sasikanth Manne, Jean-Christophe Beltra, Erietta Stelekati, Zeyu Chen, Kito Nzingha, Mohammed-Alkhatim Ali, John L. Johnson, Josephine R. Giles, Divij Mathew, Allison R. Greenplate, Golnaz Vahedi, E. John Wherry
Journal: Nature Immunology (2021)
Supplementing SARS-CoV-2 genomic surveillance with PCR-based variant detection for real-time actionable information, the Netherlands, June to July 2021
Authors: Richard Molenkamp, Ewout Fanoy, Leonie Derickx, Theun de Groot, Marcel Jonges, Tjalling Leenstra, Roel Nijhuis, Suzan Pas, Ali Vahidnia, Christian von Wintersdorff, Bert Mulder, Marion Koopmans
Journal: Eurosurveillance (2021)

We evaluated routine testing with SARS-CoV-2 Delta variant-specific RT-PCR in regional hospital laboratories in addition to centralised national genomic surveillance in the Netherlands during June and July 2021. The increase of the Delta variant detected by RT-PCR correlated well with data from genomic surveillance and was available ca 2 weeks earlier. This rapid identification of the relative abundance and increase of SARS-CoV-2 variants of concern may have important benefits for implementation of local public health measures.
1107P Durvalumab plus tremelimumab in patients with grade 3 neuroendocrine neoplasms of gastroenteropancreatic origin: Updated results from the multicenter phase II DUNE trial (GETNE 1601)
Authors: J. Capdevila, S. Landolfi, J. Hernando, A. Teule, R. Garcia-Carbonero, A. Custodio, A. Cubillo, T. Alonso-Gordoa, A. Carmona-Bayonas, G. Crespo, M. Blanco, A. Viudez, A. La Casta, I. Sevilla, Á. Segura, C. López, M. Benavent Viñuales, P. Nuciforo, J.L. Manzano
Journal: Annals of Oncology (2021)
655MO A prospective phase II trial of cabazitaxel in male patients with chemotherapy pre-treated metastatic germ-cell tumors: The CABA-GCT study
Authors: G. Baciarello, S. Cyrille, G. Gravis, A. Fléchon, C.M. Chevreau, M. Deblock, E. Colomba, P. Lavaud, R. Flippot, K. Malekzadeh, G. Le Teuff, K. Fizazi
Journal: Annals of Oncology (2021)
HBVおよびHCV流行地域における原発性肝癌患者スクリーニングの最も強力なリスク係数としてのHBsAg、抗HCVおよびアルファフェト・タンパク質
Authors: Tanabe G, Shimazu H, Aiko T, Kurita K, Hamanoue M, Ueno S, Kobayashi Y, Mitsue S, Tsubouchi H, Maeda E, Shou Y, Arima T
Journal: Hepatology (1992)
835P Enhancement of the International Prognostic Index with hematologic parameters: A new prognostic model for diffuse large B-cell lymphoma treated with R-CHOP
Authors: H. Chen, Q. Zhong, Y. Qin, J. Yang, P. Liu, X. He, S. Zhou, C. Zhang, L. Gui, S. Yang, L. Zhou, Y. Shi
Journal: Annals of Oncology (2021)
CN11 Impact of a surgical ward breakfast buffet on nutritional intake in postoperative (oncological) patients
Authors: S. Musters, H. van Noort, S. van Dieren, S. Geelen, J. Maaskant, W. Bemelman, E. Nieveen van Dijkum, M. Besselink, A. Eskes
Journal: Annals of Oncology (2021)
1587P SARS-CoV-2 infection risk and COVID-19 prevalence in cancer patients during the first wave of COVID-19 pandemic in a Northern Italy’s virus epicenter area
Authors: A. Musolino, B. Pellegrino, L. Isella, C. Tommasi, F. Pucci, A. Leonetti, E. Rapacchi, F. Leonardi, S. Bizzoco, P. Affanni, L. Veronesi, P. Sgargi, G. Maglietta, M. Michiara
Journal: Annals of Oncology (2021)